
PRGO Valuation
Perrigo Company PLC
PRGO Relative Valuation
PRGO's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PRGO is overvalued; if below, it's undervalued.
Historical Valuation
Perrigo Company PLC (PRGO) is now in the Undervalued zone, suggesting that its current forward PE ratio of 6.66 is considered Undervalued compared with the five-year average of 12.76. The fair price of Perrigo Company PLC (PRGO) is between 64.39 to 84.22 according to relative valuation methord. Compared to the current price of 20.74 USD , Perrigo Company PLC is Undervalued By 67.79%.
Relative Value
Fair Zone
64.39-84.22
Current Price:20.74
67.79%
Undervalued
6.66
PE
1Y
3Y
5Y
Trailing
Forward
7.90
EV/EBITDA
Perrigo Company PLC. (PRGO) has a current EV/EBITDA of 7.90. The 5-year average EV/EBITDA is 11.03. The thresholds are as follows: Strongly Undervalued below 7.16, Undervalued between 7.16 and 9.09, Fairly Valued between 12.96 and 9.09, Overvalued between 12.96 and 14.89, and Strongly Overvalued above 14.89. The current Forward EV/EBITDA of 7.90 falls within the Undervalued range.
9.06
EV/EBIT
Perrigo Company PLC. (PRGO) has a current EV/EBIT of 9.06. The 5-year average EV/EBIT is 12.79. The thresholds are as follows: Strongly Undervalued below 7.80, Undervalued between 7.80 and 10.29, Fairly Valued between 15.29 and 10.29, Overvalued between 15.29 and 17.79, and Strongly Overvalued above 17.79. The current Forward EV/EBIT of 9.06 falls within the Undervalued range.
20.74
PS
Perrigo Company PLC. (PRGO) has a current PS of 20.74. The 5-year average PS is 1.08. The thresholds are as follows: Strongly Undervalued below -0.96, Undervalued between -0.96 and 0.06, Fairly Valued between 2.10 and 0.06, Overvalued between 2.10 and 3.12, and Strongly Overvalued above 3.12. The current Forward PS of 20.74 falls within the Strongly Overvalued range.
6.26
P/OCF
Perrigo Company PLC. (PRGO) has a current P/OCF of 6.26. The 5-year average P/OCF is 10.73. The thresholds are as follows: Strongly Undervalued below 4.12, Undervalued between 4.12 and 7.42, Fairly Valued between 14.03 and 7.42, Overvalued between 14.03 and 17.34, and Strongly Overvalued above 17.34. The current Forward P/OCF of 6.26 falls within the Undervalued range.
7.38
P/FCF
Perrigo Company PLC. (PRGO) has a current P/FCF of 7.38. The 5-year average P/FCF is 10.68. The thresholds are as follows: Strongly Undervalued below 5.17, Undervalued between 5.17 and 7.92, Fairly Valued between 13.43 and 7.92, Overvalued between 13.43 and 16.18, and Strongly Overvalued above 16.18. The current Forward P/FCF of 7.38 falls within the Undervalued range.
Perrigo Company PLC (PRGO) has a current Price-to-Book (P/B) ratio of 0.64. Compared to its 3-year average P/B ratio of 0.87 , the current P/B ratio is approximately -26.48% higher. Relative to its 5-year average P/B ratio of 0.94, the current P/B ratio is about -32.40% higher. Perrigo Company PLC (PRGO) has a Forward Free Cash Flow (FCF) yield of approximately 8.48%. Compared to its 3-year average FCF yield of 5.33%, the current FCF yield is approximately 59.00% lower. Relative to its 5-year average FCF yield of 4.04% , the current FCF yield is about 109.67% lower.
0.64
P/B
Median3y
0.87
Median5y
0.94
8.48
FCF Yield
Median3y
5.33
Median5y
4.04
Competitors Valuation Multiple
The average P/S ratio for PRGO's competitors is 58.03, providing a benchmark for relative valuation. Perrigo Company PLC Corp (PRGO) exhibits a P/S ratio of 20.74, which is -64.26% above the industry average. Given its robust revenue growth of -0.86%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap

PRGO.N
Perrigo Company PLC
20.74
Average P/S: 58.03
-0.86%
2.85B

SUPN.O
Supernus Pharmaceuticals Inc
55.13
-1.71%
3.46B

KNSA.O
Kiniksa Pharmaceuticals International PLC
37.01
61.17%
2.81B

BLTE.O
Belite Bio Inc
105.91
3.68B

PBH.N
Prestige Consumer Healthcare Inc
60.60
-6.59%
2.98B

TARS.O
Tarsus Pharmaceuticals Inc
68.81
151.54%
2.90B
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PRGO decreased by 26.59% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -27.67 to -48.09.
The secondary factor is the Revenue Growth, contributed -0.86%to the performance.
Overall, the performance of PRGO in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch

FA
First Advantage Corp
12.630
USD
-2.55%

BTSG
Brightspring Health Services Inc
33.050
USD
+0.79%

VEON
VEON Ltd
48.150
USD
+1.25%

LPL
LG Display Co Ltd
5.010
USD
+3.94%

WD
Walker & Dunlop Inc
79.920
USD
-0.15%

IPGP
IPG Photonics Corp
85.120
USD
+1.20%

LIF
Life360 Inc
98.710
USD
+2.88%

FBP
First BanCorp
19.490
USD
+0.05%

AVPT
AvePoint Inc
14.070
USD
-0.42%
FAQ
Is Perrigo Company PLC (PRGO) currently overvalued or undervalued?
Perrigo Company PLC (PRGO) is now in the Undervalued zone, suggesting that its current forward PE ratio of 6.66 is considered Undervalued compared with the five-year average of 12.76. The fair price of Perrigo Company PLC (PRGO) is between 64.39 to 84.22 according to relative valuation methord. Compared to the current price of 20.74 USD , Perrigo Company PLC is Undervalued By 67.79% .





